276 related articles for article (PubMed ID: 33040991)
1. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
McDonald JS; McDonald RJ
Magn Reson Imaging Clin N Am; 2020 Nov; 28(4):497-507. PubMed ID: 33040991
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.
Davies J; Siebenhandl-Wolff P; Tranquart F; Jones P; Evans P
Arch Toxicol; 2022 Feb; 96(2):403-429. PubMed ID: 34997254
[TBL] [Abstract][Full Text] [Related]
3. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.
McDonald RJ; Levine D; Weinreb J; Kanal E; Davenport MS; Ellis JH; Jacobs PM; Lenkinski RE; Maravilla KR; Prince MR; Rowley HA; Tweedle MF; Kressel HY
Radiology; 2018 Nov; 289(2):517-534. PubMed ID: 30204075
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.
Delfino R; Biasotto M; Candido R; Altissimo M; Stebel M; Salomè M; van Elteren JT; Vogel Mikuš K; Zennaro C; Šala M; Addobbati R; Tromba G; Pascolo L
Toxicol Lett; 2019 Feb; 301():157-167. PubMed ID: 30476537
[TBL] [Abstract][Full Text] [Related]
6. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
Holowka S; Shroff M; Chavhan GB
Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.
Mathur M; Jones JR; Weinreb JC
Radiographics; 2020; 40(1):153-162. PubMed ID: 31809230
[TBL] [Abstract][Full Text] [Related]
8. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
Bäuerle T; Saake M; Uder M
Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
[TBL] [Abstract][Full Text] [Related]
10. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
Abraham JL; Edward M
AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
[No Abstract] [Full Text] [Related]
11. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
Ramalho J; Semelka RC; Ramalho M; Nunes RH; AlObaidy M; Castillo M
AJNR Am J Neuroradiol; 2016 Jul; 37(7):1192-8. PubMed ID: 26659341
[TBL] [Abstract][Full Text] [Related]
13. Where does the gadolinium go? A review into the excretion and retention of intravenous gadolinium.
Sharma P; Cheng J; Coulthard A
J Med Imaging Radiat Oncol; 2023 Oct; 67(7):742-752. PubMed ID: 37665796
[TBL] [Abstract][Full Text] [Related]
14. High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification.
Barbieri S; Schroeder C; Froehlich JM; Pasch A; Thoeny HC
Contrast Media Mol Imaging; 2016 May; 11(3):245-50. PubMed ID: 26929131
[TBL] [Abstract][Full Text] [Related]
15. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.
Noda SM; Oztek MA; Stanescu AL; Maloney E; Shaw DWW; Iyer RS
Pediatr Radiol; 2022 Feb; 52(2):345-353. PubMed ID: 33978802
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis: some considerations on the debate regarding its cause.
Provenzale JM
AJR Am J Roentgenol; 2008 Dec; 191(6):1867-9. PubMed ID: 19020262
[No Abstract] [Full Text] [Related]
18. Gadolinium Retention and Breast MRI Screening: More Harm Than Good?
Sardanelli F; Cozzi A; Trimboli RM; Schiaffino S
AJR Am J Roentgenol; 2020 Feb; 214(2):324-327. PubMed ID: 31799869
[No Abstract] [Full Text] [Related]
19. Gadolinium-based contrast agents in children.
Rozenfeld MN; Podberesky DJ
Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
[TBL] [Abstract][Full Text] [Related]
20. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
